Still early stage, but this Flagship upstart recruited a Big Pharma exec with a $4.3M compensation package and an IPO plan
Back last spring when Novartis vet Bill Hinshaw was wooed by his old boss to take the helm at Flagship startup Axcella Health, he said he was ready to take a risk in making the leap from pharma multinational to a little startup in Cambridge.
“In Big Pharma, you can paint on a big canvas and that’s compelling at different stages, but there’s innovative power available right now in biotech,” Hinshaw told Endpoints News.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.